Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Total revenues	$ 26,366	$ 50,126	$ 70,345	$ 86,642
Kyprolis
Disaggregation of Revenue [Line Items]
Total revenues	20,430	17,820	37,584	31,252
Kyprolis
Disaggregation of Revenue [Line Items]
Total revenues	8,097	7,127	14,325	11,749
Evomela
Disaggregation of Revenue [Line Items]
Total revenues	2,357	2,394	4,907	5,095
Teriparatide injection
Disaggregation of Revenue [Line Items]
Total revenues	3,613	5,502	7,113	8,413
Rylaze
Disaggregation of Revenue [Line Items]
Total revenues	3,028	2,317	5,637	3,966
Other
Disaggregation of Revenue [Line Items]
Total revenues	3,335	480	5,602	2,029
Captisol
Disaggregation of Revenue [Line Items]
Total revenues	5,220	29,545	15,842	41,667
Captisol - Core
Disaggregation of Revenue [Line Items]
Total revenues	5,220	3,325	15,842	9,551
Captisol - COVID
Disaggregation of Revenue [Line Items]
Total revenues	0	26,220	0	32,116
Contract revenue
Disaggregation of Revenue [Line Items]
Total revenues	716	2,761	16,919	13,723
License Fees
Disaggregation of Revenue [Line Items]
Total revenues	508	558	622	2,639
Milestone
Disaggregation of Revenue [Line Items]
Total revenues	0	0	15,300	5,993
Other
Disaggregation of Revenue [Line Items]
Total revenues	$ 208	$ 2,203	$ 997	$ 5,091